Alleviation of temporomandibular joint osteoarthritis by targeting RIPK1‐mediated inflammatory signalling
Journal of Cellular and Molecular Medicine · 2024
DOI: 10.1111/jcmm.17929 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Cellular and Molecular Medicine, 2024. Verfasst von Xin Cao und 6 weiteren Autor:innen. Beteiligte Einrichtung: College of Stomatology, Chongqing Medical University, Chongqing, China. Hauptthemen laut MEDLINE: Receptor-Interacting Protein Serine-Threonine Kinases, Osteoarthritis, Signal Transduction, NF-kappa B. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 60 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Chongqing, China, Natural Science Foundation of Chongqing.
Abstract (Originalsprache)
Temporomandibular joint osteoarthritis (TMJOA), prevalent in adolescents and the elderly, has serious physical and psychological consequences. TMJOA is a degenerative disease of the cartilage and bone, mostly driven by inflammation, and synoviocytes are the first and most important inflammatory factor releasers. Receptor‐interacting serine/threonine‐protein kinase (RIPK1) promotes inflammatory response and cell death during an array of illnesses. This research aimed to explore the impacts of RIPK1 inhibitor therapy in TMJOA and the mechanism of RIPK1 in inducing inflammation during TMJOA. Herein, inhibition of RIPK1 suppressed the elevated levels of inflammatory factors, nuclear factor kappa B (NF‐κB), along with markers of apoptosis and necroptosis after tumour necrosis factor (TNF)‐α/cycloheximide (CHX) treatment in synoviocytes. Moreover, inflammation models were constructed in vivo through complete Freund's adjuvant (CFA) induction and disc perforation, and the findings supported that RIPK1 inhibition protected TMJ articular cartilage against progressive degradation. RIPK1 regulates NF‐κB activation via cellular inhibitor of apoptosis proteins (cIAP), apoptosis via caspase‐8, and necroptosis via RIPK3/mixed lineage kinase domain‐like (MLKL) in synoviocytes, which in turn facilitates TMJOA inflammation progression.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- College of Stomatology, Chongqing Medical University, Chongqing, China.
- Chongqing Key Laboratory of Oral Diseases and Biomedical Sciences, Chongqing, China.
- Chongqing Municipal Key Laboratory of Oral Biomedical Engineering of Higher Education, Chongqing, China.
ORCID-Profile: Xin Cao
Förderung
- National Natural Science Foundation of China
- Natural Science Foundation of Chongqing, China
- Natural Science Foundation of Chongqing
Zitieren
APA
Cao, X., Peng, S., Yan, Y., Li, J., Zhou, J., Dai, H., & Xu, J. (2024). Alleviation of temporomandibular joint osteoarthritis by targeting RIPK1‐mediated inflammatory signalling. Journal of Cellular and Molecular Medicine. https://doi.org/10.1111/jcmm.17929
Vancouver
Cao X, Peng S, Yan Y, Li J, Zhou J, Dai H, et al. Alleviation of temporomandibular joint osteoarthritis by targeting RIPK1‐mediated inflammatory signalling. Journal of Cellular and Molecular Medicine. 2024. doi:10.1111/jcmm.17929
BibTeX
@article{Cao2024,
author = {Cao, Xin and Peng, Sisi and Yan, Ying and Li, Jun and Zhou, Jianping and Dai, Hongwei and Xu, Jie},
title = {Alleviation of temporomandibular joint osteoarthritis by targeting RIPK1‐mediated inflammatory signalling},
journal = {Journal of Cellular and Molecular Medicine},
year = {2024},
doi = {10.1111/jcmm.17929}
}
EUVIMED